Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;42(1 suppl 1):215-231.
doi: 10.1590/1678-4685-GMB-2018-0104. Epub 2019 Apr 29.

Reviewing the Characteristics of BRCA and PALB2-related Cancers in the Precision Medicine Era

Free PMC article

Reviewing the Characteristics of BRCA and PALB2-related Cancers in the Precision Medicine Era

Gabriel S Macedo et al. Genet Mol Biol. .
Free PMC article


Germline mutations in BRCA1 and BRCA2 (BRCA) genes confer high risk of developing cancer, especially breast and ovarian tumors. Since the cloning of these tumor suppressor genes over two decades ago, a significant amount of research has been done. Most recently, monoallelic loss-of-function mutations in PALB2 have also been shown to increase the risk of breast cancer. The identification of BRCA1, BRCA2 and PALB2 as proteins involved in DNA double-strand break repair by homologous recombination and of the impact of complete loss of BRCA1 or BRCA2 within tumors have allowed the development of novel therapeutic approaches for patients with germline or somatic mutations in said genes. Despite the advances, especially in the clinical use of PARP inhibitors, key gaps remain. Now, new roles for BRCA1 and BRCA2 are emerging and old concepts, such as the classical two-hit hypothesis for tumor suppression, have been questioned, at least for some BRCA functions. Here aspects regarding cancer predisposition, cellular functions, histological and genomic findings in BRCA and PALB2-related tumors will be presented, in addition to an up-to-date review of the evolution and challenges in the development and clinical use of PARP inhibitors.


Figure 1
Figure 1. Frequent alterations arising in breast and ovarian tumors from patients carrying germline mutations in BRCA1 and BRCA2. For details, see Ref 1 (Kurian et al., 2017), Ref 2 (Maxwell et al., 2017) and Ref3 (Network, 2011).

Similar articles

See all similar articles

Cited by 2 articles


    1. Agnarsson BA, Jonasson JG, Björnsdottir IB, Barkardottir RB, Egilsson V, Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat. 1998;47:121–127. - PubMed
    1. Al-Mulla F, Bland JM, Serratt D, Miller J, Chu C, Taylor GT. Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol. 2009;62:350–356. - PMC - PubMed
    1. Alemar B, Gregório C, Herzog J, Matzenbacher Bittar C, Brinckmann Oliveira C, Netto, Artigalas O, D Schwartz IV, Coffa J, Alves Camey S, Weitzel J, et al. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population? PLoS One. 2017;12:e0187630. - PMC - PubMed
    1. Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, Green AR. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Res Treat. 2015;150:81–90. - PMC - PubMed
    1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. - PMC - PubMed

Internet Resources

    1. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Hereditary Breast and/or Ovarian Cancer. Version 1.2018. 2017. - NCCN - National Comprehensive Cancer Network.